Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...

Jim Cramer believes Uranium Energy Corp. is going higher, thanks to a recent acquisition deal. Novo Nordisk faces antitrust concerns while Halliburton gets a Buy rating from BofA Securities.

AZN currently has a forward P/E ratio of 19.02, while NVO has a forward P/E of 39.15. We also note that AZN has a PEG ratio ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

A study will assess changes in employment status and sick days when people take the drug. Weight loss drugs could be given to unemployed people with obesity as a way of getting them into work, British ...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...

Wylie said: "Ozempic (semaglutide) is a medication licensed for the management of type 2 diabetes. While it has shown ...

Novo Nordisk filed suit against another semaglutide compounder on Friday, bringing its total number of cases to 50. Both Novo ...

France’s Economy Minister has warned that the government could block the sale of a subsidiary of the French pharmaceutical ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...